The study of epithelioid angiomyolipoma (EAML) and related renal tumours has illuminated a complex landscape of diagnostic challenges and evolving treatment approaches. EAML is a rare variant of the ...
A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.
January 10, 2008 — Year-long treatment with the immunosuppressive drug sirolimus led to shrinkage of angiomyolipoma tumors, with volume reduced by nearly 50%, along with improvement in lung function ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results